Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature.
Ty Moore, Austin Quick, Wilder Widman et al.
✦ AI-curated · Sources linked
Case in brief
A 60-year-old woman with metastatic small cell carcinoma of the anal canal was treated with a regimen based on small cell lung cancer protocols. She initially responded to platinum-based chemotherapy combined with the immune checkpoint inhibitor atezolizumab. After disease progression, she received lurbinectedin and tarlatamab, resulting in a partial response, illustrating the potential of adapting lung cancer therapies for extrapulmonary small cell carcinoma.
Diagnostic / clinical pearl
This case underscores the potential efficacy of small cell lung cancer treatments in extrapulmonary small cell carcinoma, highlighting the need for individualized therapy in rare malignancies.
Why it matters
The findings emphasize the importance of ongoing clinical reporting and research to refine treatment strategies for rare neuroendocrine tumors, which may benefit from therapies originally designed for more common cancers.